- Home
- GRX vs ADCT Comparison
GRX vs ADCT Comparison
Compare GRX & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRX
- ADCT
- Stock Information
- Founded
- GRX 2007
- ADCT 2011
- Country
- GRX United States
- ADCT Switzerland
- Employees
- GRX N/A
- ADCT N/A
- Industry
- GRX Finance/Investors Services
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- GRX Finance
- ADCT Health Care
- Exchange
- GRX Nasdaq
- ADCT Nasdaq
- Market Cap
- GRX 154.8M
- ADCT 127.9M
- IPO Year
- GRX N/A
- ADCT 2020
- Fundamental
- Price
- GRX $9.47
- ADCT $1.28
- Analyst Decision
- GRX
- ADCT Strong Buy
- Analyst Count
- GRX 0
- ADCT 5
- Target Price
- GRX N/A
- ADCT $7.75
- AVG Volume (30 Days)
- GRX 39.7K
- ADCT 245.0K
- Earning Date
- GRX 01-01-0001
- ADCT 05-14-2025
- Dividend Yield
- GRX 5.98%
- ADCT N/A
- EPS Growth
- GRX N/A
- ADCT N/A
- EPS
- GRX 0.26
- ADCT N/A
- Revenue
- GRX N/A
- ADCT $70,837,000.00
- Revenue This Year
- GRX N/A
- ADCT $6.82
- Revenue Next Year
- GRX N/A
- ADCT $18.56
- P/E Ratio
- GRX $38.50
- ADCT N/A
- Revenue Growth
- GRX N/A
- ADCT 1.84
- 52 Week Low
- GRX $7.73
- ADCT $1.05
- 52 Week High
- GRX $10.40
- ADCT $4.83
- Technical
- Relative Strength Index (RSI)
- GRX 42.89
- ADCT 43.00
- Support Level
- GRX $9.60
- ADCT $1.23
- Resistance Level
- GRX $9.91
- ADCT $1.49
- Average True Range (ATR)
- GRX 0.14
- ADCT 0.08
- MACD
- GRX 0.01
- ADCT 0.00
- Stochastic Oscillator
- GRX 37.32
- ADCT 25.00
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).